Janssen Research & Development, Llc

This study tests whether adding the drug talquetamab to standard treatments (daratumumab and pomalidomide) helps people with multiple myeloma that has come back or stopped responding to prior therapy. About 864 participants will receive one of three drug combinations. The main go…

This study tests an oral medication called JNJ-77242113 for people with moderate to severe plaque psoriasis. About 684 adults will receive either the drug or a placebo to see if it can clear or greatly improve their skin. The trial also includes a withdrawal phase to see how long…

This study tests an experimental drug, JNJ-77242113, to see how well it clears skin plaques in people with moderate to severe psoriasis. About 752 adults will receive either the new drug, a placebo (inactive pill), or an existing treatment (ustekinumab). The main goal is to measu…

This study tests a drug called guselkumab in children aged 2-17 with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and sores. The goal is to see if the drug can bring about remission—meaning no symptoms and healed gut lining—by week 56. About…

This phase 3 study tests whether a single infusion of cilta-cel (a CAR-T cell therapy) after initial chemotherapy can delay cancer progression better than standard long-term maintenance therapy in people newly diagnosed with multiple myeloma who cannot have a stem cell transplant…

This program provides early access to teclistamab for people with relapsed or refractory multiple myeloma who have run out of standard treatment options. Participants must have tried all available therapies, including proteasome inhibitors, IMiDs, and anti-CD38 antibodies. The go…

This study tests an investigational drug called nipocalimab in 36 adults with active myositis, a condition causing muscle inflammation and weakness. Participants receive either nipocalimab or a placebo to see if the drug improves muscle strength and function while allowing lower …

This early-stage study tests a new drug called ARX517, alone or with other treatments, in men with metastatic prostate cancer (cancer that has spread). The main goal is to check the drug's safety and find the best dose. About 183 men will take part in this study.

This study tests a new drug called teclistamab in about 194 people with multiple myeloma, a type of blood cancer, that has returned or not responded to prior treatments. The drug is designed to help the immune system attack cancer cells. The main goal is to see how many patients …

This study tests a combination of two targeted drugs, amivantamab and capmatinib, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the drugs can shrink tumors. About 57 adults with specific genetic changes (MET mutat…

This study tests whether guselkumab can reduce spine-related symptoms and inflammation in people with active psoriatic arthritis. About 411 participants who have not used biologic drugs before will receive either guselkumab or a placebo. The main goal is to see if symptoms like b…

This study tests a combination of two drugs, amivantamab and cetrelimab, in people with advanced non-small cell lung cancer that has spread. The goal is to find the best dose and see if the combination can shrink tumors. About 71 participants will take part, and the study tracks …

This study tests whether adding the drug niraparib to standard therapy (abiraterone and prednisone) can help men with metastatic prostate cancer that no longer responds to hormone therapy. About 765 participants received either the combo or a placebo. The main goal is to see if t…

This study tests an experimental drug called nipocalimab in 655 adults with moderate to severe Sjogren's disease, an autoimmune condition causing dry eyes and mouth. The goal is to see if the drug reduces disease activity over 48 weeks compared to a placebo. Participants must hav…

This early-phase study tests a new drug called talquetamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 166 participants will be enrolled.

This study tests a new drug called amivantamab, which targets two proteins on lung cancer cells. It is given alone or with other treatments to people with advanced non-small cell lung cancer that has spread or cannot be removed. The goal is to find safe doses and see if the drug …

This early-stage study tests a new drug (JNJ-87801493) combined with immune-boosting T-cell engagers in about 70 people whose B-cell non-Hodgkin lymphoma has returned or not responded to other treatments. The main goals are to check safety and find the best dose. This is not a cu…

This study tests whether a daily pill called milvexian can help prevent another stroke in people who have recently had a stroke or a high-risk mini-stroke. Over 12,500 adults took either milvexian or a placebo for about a year. The goal is to see if the drug reduces the chance of…

This study tests a gene therapy given to the second eye of people with X-linked retinitis pigmentosa, a genetic condition that causes vision loss. The therapy uses a harmless virus to deliver a working gene to the retina. Researchers will check safety and whether it improves visi…

This study tests a new treatment (TAR-200, a drug-releasing device placed in the bladder) alone or with another drug (cetrelimab) against the standard BCG therapy for people with a high-risk type of bladder cancer that hasn't spread into the muscle. About 1,135 participants who h…

This study tests a combination of two immune-boosting antibodies, talquetamab and teclistamab, in people with multiple myeloma that has returned or stopped responding to treatment. The goal is to find the safest and most effective dose and to see how well the drugs shrink tumors.…

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe ulcerative colitis. About 577 adults who haven't responded well to other advanced treatments will take part. The goal is to see if the co…

This study tests different sequences of advanced therapies (Cilta-cel, Tal-D, and Tec-D) after initial treatment in 43 people with newly diagnosed, standard-risk multiple myeloma. The goal is to see if these combinations can lead to a deep, lasting remission that might be a cure.…

This early-stage study tests a new drug, JNJ-80948543, designed to help the body's immune cells attack cancer. It is for adults with certain blood cancers (non-Hodgkin lymphoma or chronic lymphocytic leukemia) that have not responded to other treatments. The main goals are to che…

This study tests a combination of two treatments, ciltacabtagene autoleucel (a cell therapy) and talquetamab (a targeted drug), in people with high-risk multiple myeloma. The main goal is to check safety, and it also looks at how well the cancer responds. About 11 participants wh…

This study tests whether the drug daratumumab can delay or prevent smoldering multiple myeloma from turning into active multiple myeloma. About 390 people with high-risk smoldering myeloma will either receive daratumumab injections or be closely monitored without treatment. The g…

This study compares a new two-drug combination (teclistamab plus daratumumab) against two standard three-drug regimens for people whose multiple myeloma has returned or stopped responding to prior therapy. About 587 participants will be randomly assigned to receive either the new…

This study tests a drug called erdafitinib, which targets specific genetic changes in cancer cells, for people with advanced bladder cancer that has spread. About 125 participants will receive erdafitinib alone or with other treatments to see if it shrinks tumors and how safe it …

This study tests a new oral medication, JNJ-77242113, for adults with moderate to severe plaque psoriasis. It compares the drug to a placebo and another active treatment (deucravacitinib) to see how well it clears skin lesions. About 774 participants will take the pill daily for …

This study tests a drug called guselkumab in about 1,400 people with moderate to severe Crohn's disease. The goal is to see if it can reduce symptoms like abdominal pain and diarrhea, and also heal the gut lining when viewed with a camera. Participants receive either the study dr…

This study tests a new oral medication, JNJ-77242113, for people with moderate to severe plaque psoriasis. About 731 adults will receive either the new drug, a placebo (inactive pill), or an active comparator (another approved drug). The main goal is to see how well the new drug …

This study tests whether guselkumab, an injected drug, can reduce joint pain and swelling in people with active psoriatic arthritis who did not get enough relief from or could not tolerate a prior TNF-blocker. About 453 adults will receive either guselkumab or a placebo for 24 we…

This study tests a drug called guselkumab in people with active psoriatic arthritis, a condition causing joint pain, swelling, and skin plaques. The goal is to see if the drug can reduce symptoms and prevent joint damage from getting worse. About 1054 adults who have not responde…

This phase 3 study tests whether adding niraparib to standard therapy (abiraterone acetate plus prednisone) can slow cancer growth in men with metastatic castration-sensitive prostate cancer that has certain gene mutations (HRR). About 696 participants received either the combo o…

This study looks at men with metastatic prostate cancer that still responds to hormone therapy. After 6 months of standard treatment, some men will take breaks from the hormone therapy to see if it reduces hot flashes while still keeping the cancer under control. The goal is to i…

This study tests a new oral blood thinner called milvexian against the standard drug apixaban in about 20,000 adults with atrial fibrillation (an irregular heartbeat). The goal is to see if milvexian is at least as good as apixaban at preventing strokes and blood clots elsewhere …

This early-stage study tests a new drug, teclistamab, in about 300 people with multiple myeloma that has come back or not responded to other treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to find a safe dose and check for side e…

This program offers ongoing access to the drug nipocalimab for people with warm autoimmune hemolytic anemia (wAIHA) who have already shown improvement in a previous study. Participants must have completed 28 weeks of treatment and be experiencing clinical benefit, such as increas…

This phase 3 study tests whether adding daratumumab to a standard three-drug regimen (VRd) can eliminate more cancer cells in people with untreated multiple myeloma who are not eligible for a stem cell transplant. About 395 participants receive either the four-drug combination or…

This study looks at the long-term safety of the drug ustekinumab in children aged 2 to under 18 who have Crohn's disease, ulcerative colitis, or psoriatic arthritis. Participants must have already completed a prior study and shown benefit from the drug. The main goal is to track …

This study tests an oral medication called JNJ-77242113 for people with plaque psoriasis affecting special areas like the scalp, genitals, or palms and soles. About 311 adults who need systemic treatment will receive either the drug or a placebo for 16 weeks. The main goal is to …

This study tests a drug called M281 in adults with warm autoimmune hemolytic anemia, a condition where the immune system attacks red blood cells. The goal is to see if M281 can improve hemoglobin levels and reduce fatigue. About 118 participants will receive either M281 or a plac…

This early-stage study is testing an experimental drug called JNJ-88998377 in 58 people with B-cell non-Hodgkin's lymphoma that has returned or not responded to prior treatments. The main goals are to check the drug's safety and find the best dose for future studies. Participants…

This study tests a new treatment called JNJ-90009530 for adults with B-cell Non-Hodgkin lymphoma that has come back or not responded to other therapies. The treatment uses a patient's own immune cells, modified to attack cancer cells. The main goals are to find a safe dose and se…

This early-stage study tests a new drug called teclistamab combined with other cancer treatments for people with multiple myeloma, a type of blood cancer. The main goal is to check safety and find the best doses. About 140 participants who have already tried other therapies will …

This study tests whether adding two targeted drugs (amivantamab and lazertinib) to standard chemotherapy can help people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) live longer without their cancer growing. The study includes 776 adults …

This program offers talquetamab, a single-drug treatment, to people with multiple myeloma that has returned or is hard to treat. It is for those who have tried all available therapies and cannot join a clinical trial. The goal is to provide access before full approval, helping co…

This study tests a drug called guselkumab in children and teens (ages 6 to 17) with chronic plaque psoriasis, a skin condition causing red, scaly patches. The goal is to see if the drug safely clears or reduces the skin plaques. About 120 participants will receive either guselkum…

This early-stage study tests a new drug called talquetamab in people with multiple myeloma that has come back or stopped responding to other treatments. The drug is designed to help the immune system attack cancer cells. The main goals are to check safety and find the best dose f…

This study tests a new way to give the cancer drug amivantamab as a shot under the skin instead of through an IV. It includes 158 adults with advanced solid tumors that may respond to this type of treatment. The main goals are to check safety and find the best dose for the shot f…

This study tests a combination of two drugs (TAR-200 and cetrelimab) in people with muscle-invasive bladder cancer who are scheduled for bladder removal surgery but cannot or choose not to receive standard chemotherapy beforehand. The goal is to see if the drug combination can el…

This program gives patients with multiple myeloma that has come back or not responded to other treatments access to talquetamab, an experimental drug. It is for people who have no other options left. The goal is to control the disease, not cure it.

This study tests whether a combination of two drugs, amivantamab and lazertinib, works better than the current standard drug osimertinib for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). About 1,074 participants who have not had pr…

This early-phase study tested the drug apalutamide in 19 Chinese men with metastatic castration-resistant prostate cancer (mCRPC). The goal was to see how the drug moves through the body and check for side effects. Researchers also looked at changes in PSA levels, a marker of pro…

This study tests whether teclistamab, an immunotherapy, works better than standard drug combinations (PVd or Kd) for people with multiple myeloma that has come back or stopped responding after 1 to 3 prior treatments. About 614 adults will take part. The goal is to see if teclist…

This early-stage study tests a new drug (lazertinib) alone or with another drug (amivantamab) in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation). The main goals are to find safe doses and check for side effects. About 700 partici…

This study tests a new treatment called TAR-200 for people with a type of bladder cancer that came back after standard BCG therapy. TAR-200 is a device placed in the bladder that slowly releases chemotherapy. The study compares it to standard chemotherapy given directly into the …

This study tests a targeted pill (erdafitinib) against standard chemotherapy or immunotherapy for people with advanced bladder cancer that has specific FGFR gene changes. About 629 participants who have already tried other treatments will be randomly assigned to receive the new d…

This early-phase study tests a new drug combination (JNJ-80948543 plus another T-cell engager) in 19 adults with relapsed or refractory B-cell non-Hodgkin lymphoma, a type of blood cancer that has not responded to at least two prior treatments. The main goals are to find the safe…

This study tests whether a new way of making teclistamab works as well as the current version in people with multiple myeloma that has come back or stopped responding to treatment. About 108 participants will receive either the old or new version, and researchers will measure dru…

This early-stage study tests a new drug, JNJ-89853413, in about 64 adults whose acute myeloid leukemia or myelodysplastic neoplasms have returned or stopped responding to standard treatments. The main goals are to check safety, find the best dose, and see if the drug can help con…

This study tests whether combining two drugs (guselkumab and golimumab) works better than either drug alone for people with moderate to severe Crohn's disease. About 703 adults will receive the combo or a placebo to see if it improves symptoms and gut healing after 48 weeks. The …

This study tests two experimental treatments—TAR-200 (a drug placed directly into the bladder) and cetrelimab (an immunotherapy injection)—alone or together, in 220 people with high-risk bladder cancer that came back after BCG therapy. Participants cannot or choose not to have th…

This study follows people who received a gene therapy called AAV5-hRKp.RPGR for X-linked retinitis pigmentosa, a genetic eye disease that causes vision loss. Researchers are checking for side effects and measuring how well participants see over time. The goal is to understand the…

This study tests an injected drug called guselkumab for people with moderate to severe ulcerative colitis, a chronic bowel disease. About 418 adults who haven't responded well to other treatments will receive either the drug or a placebo. The main goal is to see if the drug can p…

This study tests whether combining two drugs, amivantamab and docetaxel, is safe and effective for people with advanced non-small cell lung cancer that has spread. It involves 12 adults whose cancer worsened after standard treatments. The goal is to find the best dose and see if …

This study tests a drug called erdafitinib in people with advanced bladder cancer that has certain changes in FGFR genes. The goal is to see if the drug can shrink tumors. About 239 participants will receive one of two dose schedules. The drug is taken as a pill and works by bloc…

This study tests two medicines, ustekinumab and guselkumab, in 50 children with active juvenile psoriatic arthritis (a type of arthritis that causes joint swelling and pain). The goal is to see how well the drugs work, how they move through the body, and if they are safe. Childre…

This early-stage study tests a new drug called JNJ-78278343 for men with advanced prostate cancer that has spread. The drug works by redirecting the body's immune T-cells to attack cancer cells that carry a protein called KLK2. The main goals are to find the safest and most effec…

This study tests whether the drug apalutamide can delay prostate-specific antigen (PSA) progression in Chinese men with a type of prostate cancer that no longer responds to hormone therapy but hasn't spread. The trial involves 75 participants who receive either apalutamide or a p…

This study tests whether combining the drug niraparib with other treatments can help men whose prostate cancer has spread and stopped responding to standard hormone therapy. About 136 participants will receive different drug combinations to find the safest and most effective dose…

This study tests whether a new under-the-skin (subcutaneous) version of amivantamab, given with lazertinib, works as well as the standard intravenous (IV) version in people with advanced EGFR-mutated non-small cell lung cancer that has worsened after prior treatments. About 418 p…

This study tests whether a combination of two drugs (TAR-200 and cetrelimab) can help people with a serious type of bladder cancer live longer without their cancer getting worse, compared to standard chemotherapy plus radiation. Participants are those who cannot or choose not to …

This study tests whether adding daratumumab to the standard maintenance drug lenalidomide can clear remaining cancer cells in people with multiple myeloma who still have signs of disease after a stem cell transplant. About 200 adults who recently had a transplant will receive eit…

This early-phase study tests a combination of two types of immune-boosting antibodies (talquetamab or teclistamab plus a PD-1 inhibitor) in 74 people with multiple myeloma that has returned or stopped responding to prior treatments. The main goal is to find safe doses and underst…

This early-phase study tests a new drug called JNJ-69086420 for men with advanced prostate cancer that has spread and is no longer responding to hormone therapy. The drug is an antibody linked to a radioactive particle that targets a protein found on prostate cancer cells. The st…

This program provides early access to TAR-200 for people with high-risk non-muscle invasive bladder cancer who have run out of standard treatments and cannot join a clinical trial. TAR-200 is a device placed in the bladder to deliver medication directly to the tumor. The goal is …

This study tests a drug called guselkumab in over 1,000 people with moderate to severe ulcerative colitis, a chronic bowel disease. The goal is to see if it can reduce symptoms like diarrhea and bleeding and help heal the gut lining. Participants receive either the drug or a plac…

This study tests an experimental drug called JNJ-63723283, which helps the immune system fight cancer. It is for people with advanced cancers like lung, melanoma, bladder, and others that have not responded to standard treatments. The goal is to find the best dose and see if the …

This study tests whether adding the drug amivantamab to standard chemotherapy helps people with a certain type of advanced lung cancer (EGFR Exon 20ins) live longer without their cancer growing. About 308 participants receive either the combination or chemotherapy alone. The goal…

This study tests a drug called guselkumab in 350 people with moderate to severe Crohn's disease who haven't responded well to other treatments. The goal is to see if it can reduce symptoms and heal the gut lining over 12 to 24 weeks. Participants receive either the drug or a plac…

This study tests a drug combination (daratumumab plus chemotherapy) in people newly diagnosed with AL amyloidosis, a rare condition where abnormal proteins damage organs, especially the heart. The main goals are to check heart safety and to see how the drug works in different rac…

This early-stage study tests a new drug called bleximenib combined with standard leukemia treatments for people with acute myeloid leukemia (AML) that has specific genetic changes (KMT2A or NPM1). The main goals are to find the best dose and check for side effects. About 196 part…

This early-stage study tests combinations of daratumumab (a targeted antibody) with two other drugs (talquetamab and teclistamab) in 290 adults with multiple myeloma, a type of blood cancer. The goal is to find the safest and most effective doses and to monitor side effects. Part…

This study tests a drug called golimumab in 84 children with moderate to severe ulcerative colitis, a chronic bowel disease causing inflammation and symptoms like diarrhea and bleeding. The goal is to see if the drug can bring about remission (fewer symptoms) within 6 weeks and m…

This study tests an experimental drug called JNJ-77242113 (icotrokinra) in 552 adults with active psoriatic arthritis who have not tried biologic treatments before. The goal is to see if the drug reduces joint pain, swelling, and skin symptoms better than a placebo. Participants …

This study tests a new medication called JNJ-95475939 in 256 adults with moderate to severe atopic dermatitis (eczema). The goal is to see if it reduces skin redness, itching, and rash better than a placebo. Participants receive the drug or placebo for 12 weeks, and doctors measu…

This study looks at whether special skin care can lower the chance of skin problems like rashes and nail issues in people with advanced lung cancer who are taking a combination of two drugs (amivantamab and lazertinib). About 305 participants will be randomly assigned to differen…

This study enrolls 120 people with different cancers who already received treatment in an earlier study. The goal is to track serious side effects and other health issues over time. No new treatment is given; participants are simply monitored for safety.

This study looks at how well different versions of two prostate cancer drugs, niraparib and abiraterone acetate, are absorbed by the body. About 136 men with advanced prostate cancer that no longer responds to hormone therapy will take part. The goal is to find which formulation …